Alopecia areata is an autoimmune disease resulting in hair loss that is usually in one or more coin-shaped patches on the face, scalp or other areas of the body that grows hair.

We are recruiting subjects ages 18-65 years with Alopecia Areata, to participate in a research study that evaluates the safety of an investigational study drug (IMG-007-202), and how participants with Alopecia Areata react to the study drug when given multiple times.

The research will involve two groups of people who will receive different amounts of a medication called IMG-007. The first group, called Cohort 1, will have six participants who will receive three IV (Intravenous) infusions of IMG-007, each containing 300 mg of the medication, over a period of 4 weeks. The second group, called Cohort 2, will have 24 participants who will receive three IV (Intravenous) infusions of IMG-007, each containing 600mg of the medication, over a period of 4 weeks.

Each participant will go through three phases during the study. The first is a screening phase that can last up to 5 weeks, the second phase is a 16-week treatment phase, and finally there will be an 8-week follow-up phase to monitor the participants progress after the treatment period.

The study will last a period of up to 29 weeks and includes 9 visits + 2 follow; Visits takes approximately 4-5 hrs for drug administration days and 2-3 hours for other visits.

Blood samples will be collected from all participants at each visit.

Skin biopsies (a small piece of a skin) will be taken during the study.

Compensation may be provided. Participation in this study will come at no cost to you.